Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „NovoNorm“
Suchtreffer
Begriffe & Kennungen
NovoNorm · 4.5 · In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading dose), a CYP
Eintrag öffnenNovoNorm · 4.5 · In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a mo
Eintrag öffnenNovoNorm · 4.5 · In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a mo
Eintrag öffnenNovoNorm · 4.5 · In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a mo
Eintrag öffnenNovoNorm · 4.5 · In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. Clinical d
Eintrag öffnenNovoNorm · 4.5 · In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. Clinical d
Eintrag öffnenNovoNorm · 4.5 · In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. Clinical d
Eintrag öffnenNovoNorm · 4.5 · No interaction studies have been performed in children and adolescents.
Eintrag öffnenNovoNorm · 4.5 · No interaction studies have been performed in children and adolescents.
Eintrag öffnenNovoNorm · 4.5 · No interaction studies have been performed in children and adolescents.
Eintrag öffnenNovoNorm · 4.5 · Paediatric population
Eintrag öffnenNovoNorm · 4.5 · Paediatric population
Eintrag öffnenNovoNorm · 4.5 · Paediatric population
Eintrag öffnenNovoNorm · 4.5 · Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or wa
Eintrag öffnenNovoNorm · 4.5 · Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or wa
Eintrag öffnenNovoNorm · 4.5 · Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or wa
Eintrag öffnenNovoNorm · 4.5 · Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metaboli
Eintrag öffnenNovoNorm · 4.5 · Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metaboli
Eintrag öffnenNovoNorm · 4.5 · Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metaboli
Eintrag öffnenNovoNorm · 4.5 · The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the pharmacokinetic
Eintrag öffnen